nach oben

Current Osteoporosis Reports

Erschienen in:

02.06.2016 | Osteoporosis and Cancer (M Nanes and M Drake, Section Editors)

The Bone Microenvironment: a Fertile Soil for Tumor Growth

verfasst von: Denise Buenrostro, Patrick L. Mulcrone, Philip Owens, Julie A. Sterling

Erschienen in: Current Osteoporosis Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Bone metastatic disease remains a significant and frequent problem for cancer patients that can lead to increased morbidity and mortality. Unfortunately, despite decades of research, bone metastases remain incurable. Current studies have demonstrated that many properties and cell types within the bone and bone marrow microenvironment contribute to tumor-induced bone disease. Furthermore, they have pointed to the importance of understanding how tumor cells interact with their microenvironment in order to help improve both the development of new therapeutics and the prediction of response to therapy.

Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed

Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat. 1994;32(1):73–84.CrossRefPubMed

Guise TA, Mundy GR. Cancer and bone. Endocr Rev. 1998;19(1):18–54.PubMed

Johnson RW et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling. Cancer Res. 2011;71(3):822–31.CrossRefPubMed

Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584–93.CrossRefPubMed

Coleman R et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25 Suppl 3:iii 124-37.CrossRef

Coleman R et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997–1006.CrossRefPubMed

Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010;12(6):214.CrossRefPubMedPubMedCentral

Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2–19.CrossRefPubMed

10.

Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–92.CrossRefPubMed

11.

Kostic A, Lynch CD, Sheetz MP. Differential matrix rigidity response in breast cancer cell lines correlates with the tissue tropism. PLoS One. 2009;4(7):e6361.CrossRefPubMedPubMedCentral

12.

Provenzano PP et al. Matrix density-induced mechanoregulation of breast cell phenotype, signaling, and gene expression through a FAK-ERK linkage. Oncogene. 2009;28(49):4326–43.CrossRefPubMedPubMedCentral

13.•

Page JM et al. Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin beta3 and TGF-beta receptor type II. Biomaterials. 2015;64:33–44. This paper demonstrated that the rigid mineralized bone matrix can alter gene expression and bone destruction in an integrin beta 3-TGF-β dependent manner.CrossRefPubMed

14.

Ruppender NS et al. Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One. 2010;5(11):e15451.CrossRefPubMedPubMedCentral

15.

Johnson RW et al. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis. 2014.

16.

Guo R et al. A transient cell-shielding method for viable MSC delivery within hydrophobic scaffolds polymerized in situ. Biomaterials. 2015;54:21–33.CrossRefPubMedPubMedCentral

17.

Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411–25.CrossRefPubMedPubMedCentral

18.

Guise TA et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98(7):1544–9.CrossRefPubMedPubMedCentral

19.

Wang H et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015;27(2):193–210.CrossRefPubMedPubMedCentral

20.

Schneider A et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology. 2005;146(4):1727–36.CrossRefPubMed

21.

Taichman RS et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62(6):1832–7.PubMed

22.

Sun X et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010;29(4):709–22.CrossRefPubMedPubMedCentral

23.

Jung Y et al. Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood. 2007;110(1):82–90.CrossRefPubMedPubMedCentral

24.

Jung Y et al. Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. Neoplasia. 2012;14(5):429–39.CrossRefPubMedPubMedCentral

25.

Jung Y et al. Annexin 2 is a regulator of SDF-1/CXCL12 function in the hematopoietic stem cell endosteal niche. Exp Hematol. 2011;39(2):151–166.e1.CrossRefPubMed

26.

Park, SI et al. Parathyroid hormone-related protein drives a CD11b(+)Gr1(+) cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res, 2013; 73(22), doi:10.1158/0008-5472.CAN-12-4692.

27.

Akeno N et al. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. Endocrinology. 2002;143(2):420–5.PubMed

28.

Kim JM et al. DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling. Nat Commun. 2012;3:1296.CrossRefPubMed

29.

Boyce BF, Schwarz EM, Xing L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol. 2006;18(4):427–32. doi:10.1097/01.bor.0000231913.32364.32.CrossRefPubMed

30.

Glass 2nd DA et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751–64.CrossRefPubMed

31.

Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–64.CrossRefPubMed

32.

Crockett JC et al. Bone remodelling at a glance. J Cell Sci. 2011;124(7):991–8.CrossRefPubMed

33.

Hirbe AC et al. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci U S A. 2007;104(35):14062–7.CrossRefPubMedPubMedCentral

34.

Zhou JZ et al. Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene. 2015;34(14):1831–42.CrossRefPubMed

35.•

Sottnik JL et al. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Res. 2015;75(11):2151–8. This paper presents data identifying the contribution of physical forces to tumor cell growth and that osteocytes play an important role as mediators in the bone metastatic niche.CrossRefPubMedPubMedCentral

36.

Delgado-Calle J et al. Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 2016;76(5):1089–100.CrossRefPubMed

37.

Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol. 2014;4:62.CrossRefPubMedPubMedCentral

38.

Duda DG et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010;107(50):21677–82.CrossRefPubMedPubMedCentral

39.

Calvo F et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15(6):637–46.CrossRefPubMed

40.

Harper J, Sainson RC. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Semin Cancer Biol. 2014;25:69–77.CrossRefPubMed

41.

Kraman M et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science. 2010;330(6005):827–30.CrossRefPubMed

42.

Bergfeld SA, DeClerck YA. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010;29(2):249–61.CrossRefPubMed

43.

Quante M et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257–72.CrossRefPubMedPubMedCentral

44.

Bergfeld SA, Blavier L, DeClerck YA. Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Mol Cancer Ther. 2014;13(4):962–75.CrossRefPubMedPubMedCentral

45.

Wu HC et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994;57(3):406–12.CrossRefPubMed

46.

Li X et al. Loss of TGF-beta responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res. 2012;10(4):494–503.CrossRefPubMedPubMedCentral

47.

Nakamura R et al. Transforming growth factor-beta synthesized by stromal cells and cancer cells participates in bone resorption induced by oral squamous cell carcinoma. Biochem Biophys Res Commun. 2015;458(4):777–82.CrossRefPubMed

48.

Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9(4):259–70.CrossRefPubMedPubMedCentral

49.

Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605–12.CrossRefPubMed

50.

Deng L et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol. 2010;176(2):952–67.CrossRefPubMedPubMedCentral

51.

Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008;84(3):623–30.CrossRefPubMedPubMedCentral

52.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.CrossRefPubMedPubMedCentral

53.

Biswas SK et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107(5):2112–22.CrossRefPubMed

54.

Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.CrossRefPubMed

55.

Chang MK et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol. 2008;181(2):1232–44.CrossRefPubMed

56.

Winkler IG et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood. 2010;116(23):4815–28.CrossRefPubMed

57.

Alexander KA et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res. 2011;26(7):1517–32.CrossRefPubMed

58.

Buenrostro D, Park SI, Sterling JA. Dissecting the role of bone marrow stromal cells on bone metastases. Biomed Res Int. 2014;2014:875305.CrossRefPubMedPubMedCentral

59.•

Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356–64. This paper reviews controversial issues in myeloid-derived suppressor cell biology, including their role in cancer progression and metastasis. This review also emphasis how these cells may be used both as prognostic factors and as therapeutic targets.CrossRefPubMed

60.

Youn JI et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–802.CrossRefPubMedPubMedCentral

61.

Movahedi K et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233–44.CrossRefPubMed

62.

Huang B et al. Gr-1⁺CD115⁺ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123–31.CrossRefPubMed

63.

Elkabets M et al. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010;40(12):3347–57.CrossRefPubMedPubMedCentral

64.

Srivastava MK et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70(1):68–77.CrossRefPubMed

65.

Lindau D et al. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105–15.CrossRefPubMedPubMedCentral

66.

Park SI et al. Parathyroid hormone-related protein drives a CD11b⁺Gr1⁺ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res. 2013;73(22):6574–83.CrossRefPubMed

67.

Danilin S et al. Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology. 2012;1(9):1484–94.CrossRefPubMedPubMedCentral

68.•

Sawant A et al. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 2013;73(2):672–82. This paper identified myeloid-derived suppressor cells as a novel osteoclast progenitor that had the potential to stimulate bone metastasis during cancer progression.CrossRefPubMed

69.

Vivier E et al. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12(4):239–52.CrossRefPubMed

70.

Diefenbach A et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413(6852):165–71.CrossRefPubMedPubMedCentral

71.

Liu G et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest. 2013;123(10):4410–22.CrossRefPubMedPubMedCentral

72.

Zitvogel L, Kroemer G. Cancer: antibodies regulate antitumour immunity. Nature. 2015;521(7550):35–7.CrossRefPubMed

73.

Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8(5):369–80.CrossRefPubMed

74.

Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636–45.CrossRefPubMed

75.

Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996;381(6585):751–8.CrossRefPubMed

76.

Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. Trends Immunol. 2013;34(4):169–73.CrossRefPubMed

77.

Zhang K et al. CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res. 2011;71(14):4799–808.CrossRefPubMedPubMedCentral

78.

Monteiro AC et al. T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. PLoS One. 2013;8(7):e68171.CrossRefPubMedPubMedCentral

79.

Pasquier E et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10):797–809.CrossRefPubMedPubMedCentral

80.

Ji Y et al. The role of β-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. Cell Div. 2013;8:1–1.CrossRefPubMedPubMedCentral

81.

Thaker PH et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939–44.CrossRefPubMed

82.

Thaker PH, Sood AK. The neuroendocrine impact of chronic stress on cancer. Semin Cancer Biol. 2008;18(3):164–70.CrossRefPubMed

83.

Chida Y et al. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008;5(8):466–75.CrossRefPubMed

84.

Palesh O et al. Stress history and breast cancer recurrence. J Psychosom Res. 2007;63(3):233–9.CrossRefPubMedPubMedCentral

85.

Melhem-Bertrandt A et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2645–52.CrossRefPubMedPubMedCentral

86.

Elefteriou F et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434(7032):514–20.CrossRefPubMed

87.

Campbell JP et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 2012;10(7):e1001363.CrossRefPubMedPubMedCentral

88.

Costa L et al. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer. 2008;16(8):879–89.CrossRefPubMed

89.

Käkönen S-M, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003;97(S3):834–9.CrossRefPubMed

90.

Clohisy DR and PW Mantyh. Bone cancer pain. Clin Orthop Relat Res, 2003, (415 Suppl): 279-88.

91.

Halvorson KG et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 2005;65(20):9426–35.CrossRefPubMed

92.

Falk S et al. P2X7 receptor-mediated analgesia in cancer-induced bone pain. Neuroscience. 2015;291:93–105.CrossRefPubMed

93.

Ungard RG, Seidlitz EP, Singh G. Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. Pain. 2014;155(1):28–36.CrossRefPubMed

94.

Smith MR et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46.CrossRefPubMed

95.

Le Gall C et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 2007;67(20):9894–902.CrossRefPubMed

96.

Chavez-Macgregor M et al. Angiogenesis in the bone marrow of patients with breast cancer. Clin Cancer Res. 2005;11(15):5396–400.CrossRefPubMed

97.

Kopp H-G et al. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology. 2005;20(5):349–56.CrossRefPubMed

98.•

Ghajar CM et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15(7):807–17. This paper provides evidence for a link between the vascular and tumor dormancy, a subject that had not been well studied.CrossRefPubMedPubMedCentral

Titel: The Bone Microenvironment: a Fertile Soil for Tumor Growth
verfasst von: Denise Buenrostro
Patrick L. Mulcrone
Philip Owens
Julie A. Sterling
Publikationsdatum: 02.06.2016
Verlag: Springer US
Erschienen in: Current Osteoporosis Reports / Ausgabe 4/2016
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-016-0315-2

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

15.04.2024 | Knie-TEP | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Bone Microenvironment: a Fertile Soil for Tumor Growth

Abstract

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Erratum to: Solid-State Quantitative 1H and 31P MRI of Cortical Bone in Humans

Crosstalk Between Muscle and Bone Via the Muscle-Myokine Irisin

Hajdu-Cheney Syndrome, a Disease Associated with NOTCH2 Mutations

Tissue-Level Mechanical Properties of Bone Contributing to Fracture Risk

Evolving Role of Molecular Imaging with 18F-Sodium Fluoride PET as a Biomarker for Calcium Metabolism

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Update Orthopädie und Unfallchirurgie